- Home
- SYRE
SYRE
Spyre Therapeutics Inc.
as 12-18-2024 11:43am EST
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | N/A | IPO Year: | 2016 |
| Target Price: | $48.57 | AVG Volume (30 days): | 697.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.37 - $47.97 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | -61.96% |
| Revenue Growth (this year): | 168.62% | Revenue Growth (next year): | 47.61% |
Stock Insider Trading Activity of Spyre Therapeutics Inc. (SYRE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | SYRE | Director | Nov 6 '24 | Sell | $36.76 | 6,700 | $246,312.77 | 27,360 | |
| Albers Jeffrey W. | SYRE | Director | Oct 25 '24 | Sell | $36.43 | 300 | $10,929.00 | 27,360 |
Latest Spyre Therapeutics Inc. News
SYRE Breaking Stock News: Dive into SYRE Ticker-Specific Updates for Smart Investing
PR Newswire
4 hours ago
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
PR Newswire
16 days ago
Spyre Therapeutics Announces Grants of Inducement Awards
PR Newswire
16 days ago
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
PR Newswire
23 days ago
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PR Newswire
a month ago
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
PR Newswire
a month ago
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
PR Newswire
a month ago
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
PR Newswire
a month ago
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
Compare SYRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRE Spyre Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.